301301 Stock Overview
Engages in the research and development, and industrialization of biological fermentation technology in China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Yili Chuanning Biotechnology Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥11.20 |
52 Week High | CN¥18.33 |
52 Week Low | CN¥6.94 |
Beta | 0 |
11 Month Change | -11.32% |
3 Month Change | 14.29% |
1 Year Change | 26.13% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 11.44% |
Recent News & Updates
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Shareholder Returns
301301 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -8.8% | -5.1% | -2.9% |
1Y | 26.1% | -28.2% | -20.9% |
Return vs Industry: 301301 exceeded the CN Biotechs industry which returned -28.2% over the past year.
Return vs Market: 301301 exceeded the CN Market which returned -20.9% over the past year.
Price Volatility
301301 volatility | |
---|---|
301301 Average Weekly Movement | 10.6% |
Biotechs Industry Average Movement | 6.0% |
Market Average Movement | 5.8% |
10% most volatile stocks in CN Market | 9.1% |
10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 301301's share price has been volatile over the past 3 months.
Volatility Over Time: 301301's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 2,881 | Xuheng Deng | www.klcnsw.com |
Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. It offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, desacetyl-7-aminocephalosporanic acid, and ursodeoxycholic acid.
Yili Chuanning Biotechnology Co.,Ltd. Fundamentals Summary
301301 fundamental statistics | |
---|---|
Market cap | CN¥25.21b |
Earnings (TTM) | CN¥1.12b |
Revenue (TTM) | CN¥5.08b |
22.3x
P/E Ratio4.9x
P/S RatioIs 301301 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
301301 income statement (TTM) | |
---|---|
Revenue | CN¥5.08b |
Cost of Revenue | CN¥3.40b |
Gross Profit | CN¥1.67b |
Other Expenses | CN¥554.71m |
Earnings | CN¥1.12b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | 0.50 |
Gross Margin | 32.94% |
Net Profit Margin | 22.02% |
Debt/Equity Ratio | 23.4% |
How did 301301 perform over the long term?
See historical performance and comparison